Services
Company
Legal and Governance
Publication Library / Publications
Treatment patterns and outcomes for patients with unresectable stage III and Metastatic Melanoma in the USA
Aim
To describe treatment patterns and outcomes of patients with unresectable stage III and metastatic/stage IV melanoma.
Material and Methods
An observational retrospective chart review of patients diagnosed with advanced melanoma before 1 November 2015 who initiated a new line of therapy (LOT) from 1 January 2015 to 31 May 2016.
Results
Among 487 patients, ipilimumab monotherapy (27.5%) was the most common first line of therapy (1LOT) in 2015, surpassed by nivolumab monotherapy (21.5%) in 2016. 12-month survival was ≥80.1%; proportions were highest forpatients treated with nivolumab + ipilimumab (86.6%). All treatments relatively well tolerated in real-world setting and adverse events were consistent with the previously reported safety profiles.
Conclusion
This study provides important insights into real-world advanced melanoma treatment patterns and demonstrates encouraging treatment safety and patient survival data.
Authors
A Tarhini, C Atzinger, K Gupte-Singh, C Johnson, C Macahilig, S Rao
Journal
Journal of Comparitive Effectiveness Research
Therapeutic Area
Oncology
Center of Excellence
Real-world Evidence & Data Analytics
Year
2019
Read full article